Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Marta Milà‐Alomà(University of California, San Francisco), Kaj Blennow(Sahlgrenska University Hospital), Nicholas J. Ashton(King's College London), Theresa A. Day(Eli Lilly (United States)), Armand González‐Escalante(Pasqual Maragall Foundation), Gonzalo Sánchez‐Benavides(Pasqual Maragall Foundation), Juan Lantero‐Rodriguez(University of Gothenburg), José Luís Molinuevo(Pasqual Maragall Foundation), Jeffrey L. Dage(Indiana University School of Medicine), Andréa Lessa Benedet(University of Pittsburgh), Mahnaz Shekari(Universitat Pompeu Fabra), Thomas K. Karikari(University of Pittsburgh), Gemma Salvadó(Lund University), Paula Ortiz‐Romero(Pasqual Maragall Foundation), Laia Montoliu‐Gaya(Sahlgrenska University Hospital), Juan Domingo Gispert(Lund University), Eugeen Vanmechelen(ADx NeuroSciences), Henrik Zetterberg(University of Wisconsin–Madison), Marc Suárez‐Calvet(Pasqual Maragall Foundation), Carolina Minguillón(Pasqual Maragall Foundation), Karine Fauria(Pasqual Maragall Foundation)
Cited by 349
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k